zileuton + dasatinib

Zileuton + dasatinib is a combination of two small molecule drugs with distinct mechanisms of action. Zileuton is a selective inhibitor of 5-lipoxygenase, the enzyme responsible for leukotriene synthesis from arachidonic acid. By inhibiting leukotriene formation (including LTB4, LTC4, LTD4, and LTE4), zileuton reduces inflammation and bronchoconstriction in the airways and is primarily used for prophylaxis and treatment of chronic asthma[3][4]. Dasatinib is an orally available multikinase inhibitor that targets BCR-ABL tyrosine kinase as well as several SRC-family kinases (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It binds both active and inactive conformations of ABL kinase with high affinity. Dasatinib is indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL)[1][2][5][6]. There are no approved indications or established clinical uses for this specific drug combination.